211 related articles for article (PubMed ID: 10885772)
1. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
Parren PW; Moore JP; Burton DR; Sattentau QJ
AIDS; 1999; 13 Suppl A():S137-62. PubMed ID: 10885772
[No Abstract] [Full Text] [Related]
2. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
3. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
4. Antibody neutralization of human immunodeficiency virus type 1 (HIV-1).
Schønning K
APMIS Suppl; 2003; (111):1-42. PubMed ID: 12739253
[No Abstract] [Full Text] [Related]
5. HIV-1 neutralizing antibodies: how full is the bottle?
Moore JP; Burton DR
Nat Med; 1999 Feb; 5(2):142-4. PubMed ID: 9930854
[No Abstract] [Full Text] [Related]
6. HIV/AIDS: allied responses.
Mascola JR
Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
[No Abstract] [Full Text] [Related]
7. Humoral immunity to HIV-1: neutralization and beyond.
Huber M; Trkola A
J Intern Med; 2007 Jul; 262(1):5-25. PubMed ID: 17598812
[TBL] [Abstract][Full Text] [Related]
8. Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines.
Albert J; Chiodi F; Fenyö EM
J Intern Med; 2007 Jul; 262(1):2-4. PubMed ID: 17598811
[No Abstract] [Full Text] [Related]
9. The role of neutralizing antibodies in HIV infection.
Humbert M; Dietrich U
AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
[TBL] [Abstract][Full Text] [Related]
10. Serological responses to candidate AIDS vaccines.
Graham BS
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S145-8. PubMed ID: 7865290
[No Abstract] [Full Text] [Related]
11. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
[TBL] [Abstract][Full Text] [Related]
12. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
[TBL] [Abstract][Full Text] [Related]
13. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of HIV-1 by antibody.
Sattentau QJ
Curr Opin Immunol; 1996 Aug; 8(4):540-5. PubMed ID: 8794008
[TBL] [Abstract][Full Text] [Related]
15. Antibody neutralization and escape by HIV-1.
Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 candidate vaccines can induce antibodies which share specificity with human monoclonal antibodies capable of neutralizing primary isolates.
Davis D
Vaccine; 1996 Mar; 14(4):353-4. PubMed ID: 8744564
[No Abstract] [Full Text] [Related]
17. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
[TBL] [Abstract][Full Text] [Related]
18. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
Jülg B; Goebel FD
Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
[TBL] [Abstract][Full Text] [Related]
19. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
[TBL] [Abstract][Full Text] [Related]
20. Urgently needed: a filter for the HIV-1 vaccine pipeline.
Moore JP; Burton DR
Nat Med; 2004 Aug; 10(8):769-71. PubMed ID: 15286768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
